Spinal CSF Leaks in Chronic Subdural Hematoma
Launched by UNIVERSITY OF FREIBURG · Mar 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called chronic subdural hematoma (cSDH), which is a type of bleeding in the brain that often affects older adults. Researchers want to find out how common spinal cerebrospinal fluid (CSF) leaks are in patients with cSDH. These leaks can lead to serious complications, including the cSDH itself, but they are often not diagnosed. The goal of the study is to gather more information to help doctors better identify and treat these leaks, as treatment can differ significantly based on whether a leak is present.
To participate in this trial, individuals must be 18 years or older and have imaging results showing cSDH. Those with certain conditions that prevent them from undergoing an MRI or those who have had previous treatments for cSDH may not be eligible. Participants will receive standard treatment and diagnostic tests, and their data will be collected to understand how many have spinal CSF leaks and what types are present. This information is crucial for improving care for patients with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Chronic subdural hematoma on imaging (CT/MRI)
- • 2. Age: 18 years or older
- • 3. Informed consent
- Exclusion Criteria:
- • 1. General contraindications for MRI examination (e.g., pacemaker wearers, implanted insulin, or pain pump, neurostimulator, etc.)
- • 2. Recurrent chronic subdural hematoma and previously performed diagnostics and treatment in compliance to the current cSDH SOP
- • 3. Severe brain injury, acute subdural hematoma, epidural hematoma, subarachnoid hemorrhage
About University Of Freiburg
The University of Freiburg, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and education. As a leading academic center, it fosters innovation through interdisciplinary collaboration, leveraging its extensive expertise in various fields of healthcare. The university actively sponsors clinical trials aimed at enhancing patient outcomes and advancing scientific knowledge. With a strong focus on ethical standards and rigorous methodologies, the University of Freiburg is dedicated to contributing to the development of novel therapies and improving public health through its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Freiburg, , Germany
Freiburg, Baden Württemberg, Germany
Patients applied
Trial Officials
Jürgen Beck, Prof.
Principal Investigator
Department of Neurosurgery, Medical Center, University of Freiburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported